文 献7）Osumi T, Tomizawa D, Kawai T, Sako M, Inoue E, Takimoto T, et al. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone marrow transplantation 2019; 54: 168-72.8）Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992; 3: 145-8.9）Sato M, Kako S, Matsumoto K, Oshima K, Akahoshi Y, Nakano H, et al. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. Int J Hematol 2015; 101: 497-504.10）Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai V. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012; 59: 762-4.11）Akiyama K, Kume T, Fukaya M, Shiki I, Enami T, Tatara R, et al. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoitic cell transplantation recipients. Cancer Chemother Pharmacol 2018; 82: 717-21.12）Tsujimoto SI, Shirai R, Utano T, Osumi T, Matsumoto K, Shioda Y, et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol 2020; 111: 463-466.1321）Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, et al. Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: A report from the Japanese society for hematopoietic cell transplantation. Biol blood marrow transplant 2015; 21: 2141-7.2）Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan society for hematopoietic cell transplantation. Pediatr Blood Cancer 2015; 62: 1844-50.3）Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-69.4）Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002; 100: 4344-50.5）Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383: 436-48.6）白井 了、大隅 朋、山田 悠、後藤 文、中澤 裕、塩田 曜ほか. 慢性肉芽腫症に対する用量調整ブスルファンを用いた骨髄非破壊的前処置による非血縁者間骨髄移植. 日造血細胞移植会誌 2017; 6: 152-6.
元のページ ../index.html#146